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Abstract: With approximately 240,890 new cases expected in 2011, prostate cancer remains the leading cause of non-melanoma cancer 
deaths in men. Immunotherapies using viral vector-based delivery systems targeting tumor-specific antigens are being studied. Viral 
vector-based delivery systems present tumor-targeted antigens (TAAs) to the immune system while breaking self-tolerance. Modified 
vaccinia ankara has been combined with the oncofetal antigen 5T4 to create TroVax for the treatment of castration-resistant prostate 
cancer (CRPC). The 5T4 antigen is highly expressed in a large number of carcinomas, including prostate cancer, but is rarely expressed 
in healthy tissue. TroVax has been demonstrated to be safe and highly immunogenic, both as monotherapy and in combination with 
other standard of care therapies in colorectal, renal cell, and prostate cancer. With minimal side effects and the ability to produce a strong 
immunogenic response, TroVax (MVA-5T4) is a viable addition to the treatment of prostate cancer.
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Introduction
Prostate cancer is the leading cause of non-melanoma 
cancer  deaths  in  men  with  an  estimated  240,890 
new cases for 2011.1 The largest challenge lies with 
treating  patients  who  develop  castration-resistant 
prostate  cancer  (CRPC).  Treatment  for  prostate 
cancer consists of prostatectomy, chemotherapy, and 
radiotherapy.  More  recently,  immunotherapy  has 
become of particular interest as primary therapy or 
combination  therapy. The  first  and  only  Food  and 
Drug    Administration  (FDA)  vaccine  for  prostate 
cancer to date is sipuleucel-T (Provenge). In patients 
with asymptomatic or minimally symptomatic CRPC, 
sipuleucel-T  has  been  shown  to  extend  median 
survival to 25.8 months from 21.7 months.2
Cancer vaccine development has explored using 
viral  vectors  to  elicit  an  immune  response  against 
tumor-specific antigens.3,4 Research in viral vector-
based therapy diverges into two thrusts: (1) identi-
fying the optimal tumor associated antigens (TAAs) 
and (2) identifying the most suitable delivery system. 
Cancer cells generally show some degree of genetic 
instability, which can produce an array of aberrant 
proteins  that  are  hypo-  or  hyperglycosylated  and 
highly expressed or expressed at the wrong develop-
ment stage. These proteins can be used as antigens to 
target tumor cells. Optimal TAAs are minimally, if at 
all, expressed in normal tissue and have homogenous 
high-level expression on the surface of a broad range 
of tumors. TAAs that are associated in some way with 
disease progression are of particular interest because 
of their ability to induce an immune response and also 
actively interfere with tumorigenesis.
Once  the  appropriate  TAAs  are  identified,  the 
focus becomes finding the most suitable viral vector-
based therapy to present the TAAs to elicit immunity. 
Although a wide variety of viral vectors have been 
studied, the best vectors induce potent, long-lasting 
cellular and humoral response to the TAA across a wide 
patient population without compromising the patient’s 
health and safety. Vaccinia virus, a member of the 
poxvirus family, has been developed as a recombinant 
expression vector.5,6 In animal studies, the vaccinia 
virus has been shown to produce both antibody and 
CTL responses to the exogenous proteins, which aids 
in creating an optimal environment for the induction 
of  an  efficacious  immune  response.  The  proteins 
expressed by carcinomas are usually presented to the 
immune  system  as  self-proteins  that  consequently 
elicit  no  immune  response.    Recombinant  vaccine 
viruses  expressing  murine  homologues  of  TAA, 
which are classified as self-antigens, have been shown 
to induce TAA-specific immune response in animal 
models, thus illustrating that such constructs are able 
to overcome immune tolerance to self-antigens.7 Viral 
delivery systems help break self-tolerance and trigger 
an immune response to the TAA. Such responses are 
able  to  prevent  tumor  establishment  and,  in  some 
cases, are able to actively treat established tumors. 
Recombinant  vaccinia  viruses  expressing  the  self-
antigen  CEA  has  been  constructed  and  have  been 
evaluated for toxicity and, to a lesser extent, efficacy 
in late stage colorectal cancer.8 These viruses were 
found  to  be  well  tolerated  and  both  antibody  and 
  cellular immune responses to the self-  antigen CEA 
were reported.9
The  modified  vaccinia  ankara  (MVA)  virus  has 
been extensively studied as a viral vector delivery 
system that has a well-documented safety profile and 
proven ability to generate a potent immune response. 
The antigen 5T4 is normally expressed in the placenta 
and rarely in fully developed healthy tissues;   however, 
it is highly expressed in a range of human carcinomas, 
including prostate cancer.10–12 Research about the 5T4 
antigen has linked it to altering cell adhesion,   motility, 
and morphology. The oncofetal antigen 5T4 has been 
combined with the MVA delivery virus the forma-
tion of TroVax (Oxford   BioMedica).   Consistent with 
  histology  studies  in  other  epithelial  cancers,  sig-
nificant expression of 5T4 has been detected in the 
majority of primary prostate cancers (16/19, 84%) 
studied. Unlike other self-antigen TAAs (eg, CEA), 
5T4 expression appears to be tumor specific with only 
low level expression reported in the gut. Tumor cells 
are considered poor immunogens. Although there is 
no single known mechanism to explain poor tumor 
immunogenicity in all experimental models studied, 
the molecular basis can be conceptually into 4 distinct 
groupings: (1) lack of expression of co-stimulatory 
molecules essential for effective immune induction, 
(2)  production  of  immune-inhibitory  substances, 
(3)  poor  antigen  processing  and  presentation,  and 
(4) variability in the expression of antigen by tumors. 
The first two groups are shared with normal cells in 
the body; however, the latter two have to do with the 
inherent genetic instability of cancer cells.Clinical efficacy of TroVax in castration-resistant prostate cancer
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Prostate Cancer
Prostate cancer is the most common non-  cutaneous cancer 
in men. Approximately 1 in 6 men will be   diagnosed 
with prostate cancer during their   lifetime.13 In 2011, an 
estimated 240,890 new cases of prostate   cancer will be 
diagnosed, and an estimated 33,720 men will die from 
advanced prostate   cancer. While early stage therapies 
such as prostatectomy and   radiotherapy are successful 
in about 80% of patients,14,15 the remaining 20% of 
patients and patients with advanced stages of prostate 
cancer undergo   hormonal therapies. Patients who fail 
hormonal therapy and reach CRPC disease state have a 
limited number of approved treatment options available.
Currently,  there  are  4  methods  of  treatment: 
(1) immunotherapies including sipuleucel-T, which was 
approved in 2010, (2) androgen deprivation through 
bilateral orchiectomy, Luteinizing hormone-releasing 
hormone (LHRH) agonists, or Gonadotropin releasing 
hormone (GnRH) agonists, (3) chemotherapy includ-
ing docetaxel, which was approved in 2004 and caba-
zitaxel, approved in 2010, and (4) second-line hormone 
manipulation using first-generation androgen-receptor 
antagonist, steroid hydrolyase inhibitor such as abi-
raterone  (approved  in  2011)  with  prednisone.  Only 
docetaxel, abiraterone, cabazitaxel, and sipuleucel-T 
have been approved by the FDA for the treatment of 
CRPC. These approved treatment options are palliative 
with a median overall survival of just over 2 years.
Docetaxel is a cell-cycle specific agent, which trans-
lates into being cytotoxic to all dividing cells, not just 
tumor cells. This leads to some of the common side 
effects of docetaxel, including neutropenia,   anemia, 
neuropathy,  alopecia,  and  nail  damage.    Current 
research targets therapeutic strategies that have a more 
favorable toxicity profile. Innovative therapies have 
demonstrated an increase in overall survival in com-
parison to docetaxel. Cabazitaxel was approved as a 
second-line therapy primarily based on the results of a 
phase III study that showed an increased overall median 
survival benefit of 2.4 months for men with docetaxel-
pretreated  metastatic  CRPC  receiving  cabazitaxel 
(with  prednisone)  compared  to  mitoxantrone  (with 
prednisone) (15.1 months vs. 12.7 months).16 Phase III 
trials of abiraterone demonstrated extended median 
survival by 3.6 months (15.8 months vs. 11.2 months 
in  the  placebo).17  Sipuleucel-T  has  a    demonstrated 
4-month improvement in overall survival (25.8 months 
vs.  21.7  months).2  Research  in  vaccine  treatments 
focuses on working with first-line therapies to extend 
the current overall survival rate while providing lim-
ited side effects.
While historically chemotherapy using   docetaxel 
was not considered an effective treatment for CRPC 
with a median 2 month improvement in overall sur-
vival,18 the recent ability to monitor prostate-  specific 
antigens (PSAs) has been identified as a valid surrogate 
endpoint. Monitoring the rate and degree of decline in 
PSA following radical prostatectomy, radiation ther-
apy, or androgen deprivation may help determine the 
clinical benefit of treatment. A .50% decline in serum 
PSA appears to define a subgroup of patients with 
hormone  refractory  metastatic  prostate  cancer  with 
improved survival.19–21 However, this is only an effec-
tive method of measurement in patients in the early 
stages of CRPC who have low tumor   burden. Because 
these patients have low tumor burden and a long life 
expectancy  in  comparison  to  patients  in  advanced 
stages of CRPC, they are ideal candidates for vaccine 
therapy. Prostate cancer in these patients is generally 
considered a slow-  growing tumor, which may allow 
adequate time for a   vaccine to activate the immune 
system by recognizing TAAs. A prostate cancer vac-
cine is a promising alternative therapy that aims to 
eradicate tumors with tumor-specific or   tissue-specific 
antigens, thereby   targeting specific cancer cells. How-
ever, many   antigens overly expressed or unique to 
tumor cells have been identified.
Characterization of Trovax
TAAs  can  broadly  be  divided  into  three  major 
  categories: (i) non-self-viral antigens (eg, E6/E7 from 
human  papilloma  virus),  (ii)  altered  self-  antigens 
(eg,  MUC-1),  and  (iii)  non-mutated  self-antigens 
(eg, carcinoembryonic antigen). MVA-5T4 is a non-
mutated self-antigen. As a 72-kDa surface glycoprotein, 
it is expressed in high levels in the placenta, specifically 
on trophoblasts, and in non-pregnant adult tissue, 5T4 
is highly expressed in more than 80% of carcinomas of 
the breast, renal,   colorectal, prostate, and ovaries.22,23
The exact function of 5T4 in tumor development 
has not yet been elucidated. In vitro studies of humans 
and mice have found that the over expression of 5T4 
alters cell adhesion, motility, and   morphology. The 5T4 
antigen is most often associated with tissue containing 
undifferentiated progenitor cells or differentiating cells 
engaged in migration.12 5T4 may play a common role Amato and Stepankiw
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in epitheliomesenchymal transition (EMT), a critical 
process that controls morphogenesis in multi cellular 
organisms  and  reactivates  in  the  progression  of 
carcinoma. Immunohistochemical analysis indicates 
that 5T4 expression is an indicator of poor prognosis 
in colorectal cancer.   Additionally, when tumor cells 
are transfected with the cDNA encoding for 5T4, they 
display increased motility suggesting that expression 
of  this  molecule  may  induce  metastatic  properties 
in a tumor. 5T4 expression is not evident in normal 
prostate tissues but is present at low levels in benign 
prostatic  hyperplasia  (BPH).  Expression  in  BPH 
contrasts with that identified in prostatic carcinomas. 
In BPH, expression is generally diffuse at low levels 
and  localized  to  basal  cells,  whereas  in  primary 
carcinomas, expression is generally high and does not 
show any apparent polarization. These observations 
support the hypotheses that 5T4 expression increases 
as part of malignant progression and clearly indicate 
that prostate cancer is an appropriate indication for 
5T4 targeted therapies.
Viral  vector-based  immunotherapy  presents  the 
self-antigen to the immune system in conjunction with 
a foreign viral vector, which helps overcome the poor 
immunogenicity  associated  with  TAAs.  The  most 
  studied and established viral vector is MVA, which was 
originally developed as a safe vaccine for smallpox.24 
It was derived from the vaccinia virus Ankara strain 
of more than 500 passages in primary chick embryo 
fibroblasts, after which it was found to be replication 
defective in all mammalian cell lines tested25,26 except 
Baby Hamster Kidney cells (BHK-21).27 No compli-
cations were reported when MVA was administered 
to over 120,000 recipients, many of which were at 
risk for vaccine complications.28,29
Clinical Efficacy
Preclinical  murine  models  have  demonstrated  that 
TroVax is safe and highly effective in the   prophylactic 
and  active  treatment  settings.  Clinical  trials  have 
focused on castration-resistant prostate cancer that has 
proven unresponsive to conventional systemic cytotoxic 
chemotherapy as well as metastasized renal cell cancers 
and colorectal cancers. The first study of TroVax in 
humans  was  a  dose  escalating  study  in  colorectal 
cancer patients, which demonstrated that TroVax was 
safe and well tolerated.30 To date, limited research has 
been conducted using TroVax to treat CRPC.
An  open-label,  phase  II,  single-center  study 
assessed  TroVax  alone  and  in  combination  with 
granulocyte  macrophage-colony  stimulating  factor 
(GM-CSF)  in  27  patients  with  castration-resistant 
prostate  cancer.31  Patients  received  5  ×  108  plaque-
forming  units/mL  TroVax  intramuscularly  alone  or 
in combination with 250 µg/m2 for 14 days in every 
28-day cycle for a total of 12 cycles. Of the 27 enrolled 
patients, 25 were evaluable for treatment (12 on the 
TroVax arm and 13 on the TroVax + GM-CSF arm). 
Two  patients  were  not  evaluable  due  to  clinical 
response secondary to clinical deterioration that lead to 
the inability to receive the minimum required therapy 
of 4 TroVax ± 2 GM-CSF cycles. Of the 25 evaluable 
patients,  one  was  withdrawn  due  to  a  hepatitis  C 
infection. Patients were evaluated for adverse events 
and clinical benefit, including time-to-progression (TTP). 
TTP was defined as the number of days from the day the 
subject started TroVax to the date of the subject’s disease 
progression, and it was calculated using the Kaplan-
Meier methodology. Disease progression was defined 
as at least one of the following: PSA progression (25% 
increase over baselines or nadir on at least 2 consecutive 
measurements) and an increase in the absolute PSA 
level by $5 ng/mL on at least 2 measurements at least 
2 weeks apart, new disease by bone scan, or progressive 
disease on CT scan. There were no grade 3 or 4 toxicities, 
and treatment-related adverse events include myalgia, 
bone discomfort, low-grade temperature elevation, and 
injection site irritation.
Disease  progression  was  monitored  by  quanti-
fying the levels of the surrogate marker PSA every 
4 weeks and by performing CT scans and bone scans 
every 8 weeks. All 24 patients evaluable for response 
mounted a significant 5T4-specific immune response. 
Although it was too early to comment on differences in 
survival in the two arms, the median TTP was longer in 
patients who mounted a positive 5T4   specific enzyme-
linked  immunosorbent  spot  (ELISPOT)  response. 
Patients in the TroVax alone arm had a significantly 
greater median TTP (4.05 months, range 2.30–10.30) 
compared to TroVax + GM-CSF (2.1 months, range 
1.80–6.73). Six patients showed a reduction in the rate 
of PSA change in the TroVax alone arm (n = 4) and the 
TroVax + GM-CSF arm (n = 2). All patients experienced 
disease progression, and at 14.80 months follow up, 
16 patients remained alive. There were no objective 
clinical (soft tissue or bone scan) responses; however, Clinical efficacy of TroVax in castration-resistant prostate cancer
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3 patients had a stable bone scan, 2 patients had stable 
lymph nodes on CT scan of the abdomen and pelvis, and 
4 patients had stable disease on bone scan and stable 
lymph nodes on CT scan of the abdomen and pelvis.
There were variable trends in the PSA responses 
in  the  small,  heterogonous  and  heavily  pre-treated 
  population. Eight patients in the GM-CSF arm had 
a transient dip in the PSA in the first cycle only, but 
PSA  levels  have  a  tendency  to  return  to  original 
  velocity (Tables 1 and 2). This trend was not observed 
in  the  TroVax  only  arm.  Five  patients  from  both 
arms showed maintenance in PSA during treatment. 
  Twenty-two patients showed no retardation of PSA 
velocity during treatment. The majority of patients 
showed a significant decrease in PSA velocity when 
they moved off study onto taxanes, perhaps suggest-
ing some sensitization to chemotherapy.
The study demonstrated that TroVax was safe and 
well tolerated in patients with CRPC given alone or 
in combination with GM-CSF. Furthermore, treatment 
resulted  in  a  5T4-specific  immune  response  in  all 
patients. The magnitude of the cellular responses was 
encouraging, with 7 patients developing 5T4-specific 
T-cell frequencies in excess of 1 in 10,000 peripheral 
blood  mononuclear  cells  (PBMCs)  and  10  patients 
showing 5T4 antibody titers in excess of 1,000, which 
may be important for delaying   disease progression. 
Of the 21 patients with pre-  existing MVA responses, 
10 showed a .2-fold increase in response after vac-
cination. The mean increase in MVA-specific PBMCs 
from baseline to the peak postvaccination frequency 
was 33.0-fold (range, 0.7 – $278.2) in the TroVax 
only arm and 30.3-fold (range, 0.8 – $331.1) in the 
TroVax + GM-CSF arm. Of the 9 patients who mounted 
5T4-specific response, 4 received .2 prior therapies, 
3  received  #2  prior  therapies,  and  2  had  no  prior 
therapies. In this study, GM-CSF did not convincingly 
enhance  5T4-specific  immune  responses.  Although 
5T4-specific antibody responses were induced sooner 
and were of greater magnitude in patients who received 
TroVax + GM-CSF, this difference was only marked 
after the first TroVax vaccination, and, conversely, the 
frequency of 5T4-specific cellular responses was ele-
vated in patients who received TroVax alone.
Conclusion
TroVax has consistently proven to be safe and well 
tolerated as monotherapy and in combination with 
first-line  standard-of-care  therapies,  which  include 
chemotherapeutic  agents,  cytokine  therapy,  and 
s  urgical  resection,  for  the  treatment  of  renal  cell, 
  colorectal, and prostate cancer.
A phase III trial utilizing TroVax in renal cell cancer 
patients led to the development of an immune response 
surrogate.32  This  immune  response    surrogate  helped 
identify  an  algorithm  that  predicts  patients  who  are 
most likely to mount a strong 5T4 antibody response 
based on three pre-treatment blood tests: hemoglobin, 
hematocrit, and 5T4 antibody levels. Patients who had 
higher immune response levels had an increase in sur-
vival in comparison to patients who received a placebo. 
This was retrospectively confirmed in nine histories of 
phase I and II trials of renal, colorectal, and prostate can-
cer patients. This study indicates that the immune response 
Table 1. Trovax alone arm PSA values.
Patient T4 antibody titers after X injections
0 1 2 3 4
401 0 0 160 .320 .320
402 0 0 0 160 160
403 0 0 0 .320 .320
404 0 80 80
413 160 160 160 .320 .320
414 0 40 320 .320 .320
415 0 0 40 640
416 0 160 .320 .320
421 0 0 20 160 640
422 0 0 0 160
423 0 0 320 1280
424 0 0 40
Table 2. Trovax + GM-CSF arm PSA values.
Patient 5T4 antibody titers after X injections
0 1 2 3 4
405 0 80 0
406 0 20 40
407 0 0 320
408 0 0 80 .320 160
409 0 0 160 .320 .320
410 0 0 40 80 80
411 0 160 160 .320 .320
412 0 0 80 640 320
417 0 0 80 640 640
419 40 80 320 .320 .320
420 40 .320 160 .320 .320
425 0 80 320 1280 .320Amato and Stepankiw
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surrogate could be used in future clinical trials to deter-
mine the patients who are best suited to receive TroVax.
A current phase II CRPC trial is utilizing the immune 
response surrogate. This trial will evaluate the role of 
combination therapy with TroVax plus docetaxel or 
docetaxel alone. Pre-clinical data suggested that some 
synergy might be observed by combining a taxand and 
microtubular-associated protein inhibitor estramustine 
phosphate (EMP). In subsequent randomized-based 
phase II trials, combinations with EMPdid result in 
significantly higher proportions of patients achieving 
PSA declines but at the cost of added toxicity.33 The 
administration of cytotoxic chemotherapy can result 
in bone marrow suppression and has been perceived to 
have a negative effect on immune function. However, 
data suggests that taxane-based chemotherapy may 
actually exert beneficial immunomodulatory effects 
through a variety of mechanisms, including cytokine 
production and T-cell infiltration of tumor cells.34,35 
Recently, concurrent docetaxel plus vaccine therapy 
has been safely administered without compromising 
the ability of the patient to mount a T-cell specific 
response.36 It was observed that patients who received 
a vaccine following docetaxel therapy had an increase 
in progression-free survival, and patients who crossed 
over to docetaxel post vaccine demonstrated declining 
serum PSA levels while maintaining or increasing the 
T-cell response. A review of several cancer vaccine 
studies indicated that vaccines should be given followed 
by chemotherapy to enhance immune response.37
One concentration of future research should focus 
on  patient  selection  characteristics  and  suppressing 
or  inhibiting  the  negative  effects  that  cancer  has 
on the immune system (e.g., the over expression of   
T-regulatory  cells).  Cytokines  such  as  interferon-α 
and  interleukins,  which  inhibit  and  kill  CD8  +  T 
  suppressor cells, should be investigated in   combination 
with TroVax because of their ability to suppress the 
immune  system  and  facilitate  delivery  of  TAAs. 
  Currently, evidence suggests that patients with such 
characteristics  as  minimal  tumor  burden  are  more 
likely to respond to treatment as opposed to patients 
with advanced disease. TroVax has been demonstrated 
to have some clinical benefit, and trials evaluating other 
therapies combined with TroVax should be conducted 
to evaluate any synergistic effects.
Other  concentrations  of  research  include  tumor 
suppression  via  T-cells  and  overcoming  cytotoxic 
T lymphocyte antigen-4 (CTL-4). The antigen CTL-4 
is  a  key  negative  regulator  of  adaptive  immune 
responses  and  has  a  central  role  in  maintaining 
peripheral  tolerance  and  shaping  emergent  T-cell 
responses.  Taxane-based  therapy  in  combination 
with  TroVax  may  also  help  suppress  the  immune 
system and present the TAAs. Taxane-based therapies 
promote apoptosis and disrupt cell division and may 
be a key to suppressing tumors. A current phase II trial 
is evaluating TroVax and docetaxel versus docetaxel 
alone in patients with prostate cancer to determine 
if there are any synergistic effects that would affect 
progression-free survival.38 Patients will receive up to 
10 cycles of docetaxel or 10 cycles of docetaxel plus 
TroVax.  The  study  will  compare  progression-free 
survival between the two arms.
TroVax is a promising addition to the prostate   cancer 
treatment  arsenal  as  monotherapy  or  combination 
therapy because of its minimal side effects and dem-
onstrated ability to elicit an immune response. Further 
research will help elucidate the most favorable patient 
characteristics  for  receiving  the  vaccine  and  help 
determine effective combination treatment strategies.
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